PPARγ - A new concept of treatment?

Diabetologia Croatica

Volumn 38, Issue 2, 2009, Pages 23-29

  Soldo Jureša, Dragica ^a   Metelko, Željko ^a  

^a University of Zagreb   (Croatia)

Author keywords

Diabetes mellitus; Nuclear receptor; Peroxisome proliferator activated receptors (PPARs); Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; FARGLITAZAR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; INSULIN; METAGLIDASEN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATOR; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; UNCLASSIFIED DRUG;

ANEMIA; ATHEROSCLEROSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; FLUID RETENTION; GENETIC REGULATION; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 70350707961     PISSN: 03510042     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of β-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008;10(8):617-625. (Pubitemid 352044291)
2. Cheng AYY, Leiter LA. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. Diabetes Obes Metab 2008;10:691-698.
3. Bainy ACD. Nuclear receptors and susceptibility to chemical exposure in aquatic organisms. Environ Int 2007;33:571-575.
4. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28(12):551-558. (Pubitemid 350101420)
5. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARá): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009 [Epub ahead of print]
6. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 2006;116(3):598-606. (Pubitemid 43326864)
7. Reynolds K, Goldberg RB. Thiazolidinediones beyond glycemic control. Treat Endocrinol 2006;5(1):25-36.
8. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
9. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-217. (Pubitemid 30603166)
10. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009 [Epub ahead of print]
11. Kanda Y, Matsuda M, Tawaramoto K, Kawasaki F, Hashiramoto M, Matsuki M, et al. Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanisms from pioglitazone. Diabetes Res Clin Pract 2008;81:13-18.
12. Kim HJ, Kim SK, Shim WS, Lee JH, Hur KY, Kang ES, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;81(1):42-49.
13. Chung JH, Seo AY, Chung SW, Kim MK, Leeuwenburgh Ch, Yu BP, et al. Molecular mechanism of PPAR in the regulation of agerelated inflammation. Ageing Res Rev 2008;7:126-136.
14. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735. (Pubitemid 38766357)
15. Boden G, Homko C, Mozzoli M, et al. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005;54:880-885. (Pubitemid 40322094)
16. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129-1136.
17. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108(23):2941-2948. (Pubitemid 37517824)
18. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27(1):256-263. (Pubitemid 38196741)
19. Rubenstrunk A, Hanf R, Hum DW, Fruchart JCh, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-1081. (Pubitemid 47208546)
20. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294(20):2581-2586. (Pubitemid 41697247)
21. Gerstein HC, Yusuf S, Holman R, et al. Rationale, design, and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519-1527.
22. Kahn SE, Haffner SM, Heise MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
23. Dormandly JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289. (Pubitemid 41416583)
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-2471. (Pubitemid 46919772)
25. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA 2007;298(10):1189-1195. (Pubitemid 47403105)
26. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005;48(9):1726-1735. (Pubitemid 41317825)
27. Home PD, Pocock SJ, Beck- Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357(1):28-38. (Pubitemid 47026732)
28. Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009 Feb 23. [ Epub ahead of print]